{"title":"类风湿关节炎的潜在生物标志物SPAG11B:一项双样本双向孟德尔随机分析","authors":"Kun Lin, Qi Lin, Weifeng Lv, Yao Li, Rong Su","doi":"10.1186/s41927-025-00521-y","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The incidence of rheumatoid arthritis (RA) is rising. However, its pathogenesis has not been fully understood, and the current therapeutic regimens are still limited. The aim of this study was to investigate the causal effect of plasma proteins on RA using Mendelian randomization (MR) analysis.</p><p><strong>Methods: </strong>We performed MR analysis with 4907 plasma protein genetic associations used for exposure and RA genome-wide association data used as outcomes. The method was dominated by Inverse Variance Weighting, in addition to MR-Egger and Weighted Median. Meanwhile, further external validation and reverse MR analysis were conducted to systematically assess the causal relationship between plasma proteins and RA.</p><p><strong>Result: </strong>Preliminary MR analysis identified two proteins (SPAG11B and DEFB135) associated with RA, and elevated plasma levels of both proteins would reduce the risk of RA (for SPAG11B, OR = 0.49, 95% CI = 0.40-0.61, p = 1.19 × 10<sup>- 10</sup>; for DEFB135, OR = 0.28, 95% CI = 0.15-0.52, p = 4.51 × 10<sup>- 5</sup>, using the IVW method). In the external validation phase, the results were reproducible for SPAG11B, but not for DEFB135. Reverse MR analysis pointed out that RA exhibited reverse causality for plasma levels of SPAG11B (OR = 0.93, 95% CI = 0.89-0.98, p = 0.004), but not for DEFB135 (p = 0.93).</p><p><strong>Conclusion: </strong>The results of MR analysis in this study supported that SPAG11B as a novel biomarker for RA was worthy of further investigation.</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"9 1","pages":"65"},"PeriodicalIF":2.1000,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12135468/pdf/","citationCount":"0","resultStr":"{\"title\":\"SPAG11B, a potential biomarker for rheumatoid arthritis: a two-sample bidirectional Mendelian randomization analysis.\",\"authors\":\"Kun Lin, Qi Lin, Weifeng Lv, Yao Li, Rong Su\",\"doi\":\"10.1186/s41927-025-00521-y\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The incidence of rheumatoid arthritis (RA) is rising. However, its pathogenesis has not been fully understood, and the current therapeutic regimens are still limited. The aim of this study was to investigate the causal effect of plasma proteins on RA using Mendelian randomization (MR) analysis.</p><p><strong>Methods: </strong>We performed MR analysis with 4907 plasma protein genetic associations used for exposure and RA genome-wide association data used as outcomes. The method was dominated by Inverse Variance Weighting, in addition to MR-Egger and Weighted Median. Meanwhile, further external validation and reverse MR analysis were conducted to systematically assess the causal relationship between plasma proteins and RA.</p><p><strong>Result: </strong>Preliminary MR analysis identified two proteins (SPAG11B and DEFB135) associated with RA, and elevated plasma levels of both proteins would reduce the risk of RA (for SPAG11B, OR = 0.49, 95% CI = 0.40-0.61, p = 1.19 × 10<sup>- 10</sup>; for DEFB135, OR = 0.28, 95% CI = 0.15-0.52, p = 4.51 × 10<sup>- 5</sup>, using the IVW method). In the external validation phase, the results were reproducible for SPAG11B, but not for DEFB135. Reverse MR analysis pointed out that RA exhibited reverse causality for plasma levels of SPAG11B (OR = 0.93, 95% CI = 0.89-0.98, p = 0.004), but not for DEFB135 (p = 0.93).</p><p><strong>Conclusion: </strong>The results of MR analysis in this study supported that SPAG11B as a novel biomarker for RA was worthy of further investigation.</p>\",\"PeriodicalId\":9150,\"journal\":{\"name\":\"BMC Rheumatology\",\"volume\":\"9 1\",\"pages\":\"65\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2025-06-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12135468/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMC Rheumatology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1186/s41927-025-00521-y\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Rheumatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s41927-025-00521-y","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景:类风湿关节炎(RA)的发病率呈上升趋势。然而,其发病机制尚未完全了解,目前的治疗方案仍然有限。本研究的目的是利用孟德尔随机化(MR)分析探讨血浆蛋白对类风湿关节炎的因果关系。方法:我们对4907个血浆蛋白遗传关联进行MR分析,用于暴露和RA全基因组关联数据作为结果。除MR-Egger法和加权中位数法外,该方法以方差逆加权法为主。同时,进一步进行外部验证和反向MR分析,系统评估血浆蛋白与RA的因果关系。结果:初步MR分析鉴定出两种与RA相关的蛋白(SPAG11B和DEFB135),两种蛋白的血浆水平升高会降低RA的风险(SPAG11B, OR = 0.49, 95% CI = 0.40-0.61, p = 1.19 × 10- 10;DEFB135或= 0.28,95% CI -0.52 = 0.15, p = 4.51×10 - 5,使用IVW方法)。在外部验证阶段,结果对SPAG11B是可重复的,但对DEFB135不是。反向MR分析指出RA与血浆SPAG11B水平呈反向因果关系(OR = 0.93, 95% CI = 0.89-0.98, p = 0.004),但与DEFB135水平无反向因果关系(p = 0.93)。结论:本研究的MR分析结果支持SPAG11B作为RA的新型生物标志物值得进一步研究。
SPAG11B, a potential biomarker for rheumatoid arthritis: a two-sample bidirectional Mendelian randomization analysis.
Background: The incidence of rheumatoid arthritis (RA) is rising. However, its pathogenesis has not been fully understood, and the current therapeutic regimens are still limited. The aim of this study was to investigate the causal effect of plasma proteins on RA using Mendelian randomization (MR) analysis.
Methods: We performed MR analysis with 4907 plasma protein genetic associations used for exposure and RA genome-wide association data used as outcomes. The method was dominated by Inverse Variance Weighting, in addition to MR-Egger and Weighted Median. Meanwhile, further external validation and reverse MR analysis were conducted to systematically assess the causal relationship between plasma proteins and RA.
Result: Preliminary MR analysis identified two proteins (SPAG11B and DEFB135) associated with RA, and elevated plasma levels of both proteins would reduce the risk of RA (for SPAG11B, OR = 0.49, 95% CI = 0.40-0.61, p = 1.19 × 10- 10; for DEFB135, OR = 0.28, 95% CI = 0.15-0.52, p = 4.51 × 10- 5, using the IVW method). In the external validation phase, the results were reproducible for SPAG11B, but not for DEFB135. Reverse MR analysis pointed out that RA exhibited reverse causality for plasma levels of SPAG11B (OR = 0.93, 95% CI = 0.89-0.98, p = 0.004), but not for DEFB135 (p = 0.93).
Conclusion: The results of MR analysis in this study supported that SPAG11B as a novel biomarker for RA was worthy of further investigation.